Calliditas Therapeutics Ab Patent-Cliff Exposure & CMS Drug Spending Portfolio

Calliditas Therapeutics Ab (US): 1 reconciled FDA prescription therapies, $64.8M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2043-01-01
2024 CMS Total Public Spend$64.8M
2024 Medicare Part D Spend$38.3M
2024 Medicaid Spend$26.6M
California HCAI SB 17 Filings2 WAC filings (max 28.7% 2-yr change)